Northrop Grumman Corporation (NOC) Income Statement

The 2.2% average quarterly growth over the last four quarters reflects a mature defense portfolio where volume increases from B-21 LRIP and Sentinel development are partially offset by program timing. The 5.1% growth in 2026Q2, the highest in five quarters, may indicate early production ramp benefits, but the lack of acceleration beyond mid-single digits suggests the company is not yet capturing the full potential of its backlog. Investors should monitor whether the B-21 transition to production can sustain this pace or if it remains lumpy.

The 190 basis point year-over-year decline in gross margin, despite stable revenue, suggests that early production on B-21 and Sentinel is absorbing learning-curve inefficiencies. The 2025Q1 trough of 16.7% highlights the volatility inherent in milestone-based accounting, but the recent stabilization around 19.5% may indicate that the worst of the margin pressure is passing. However, with peers like RTX at 20.1% gross margin, Northrop's structural cost base appears less efficient, warranting close monitoring of EAC adjustments on fixed-price programs.

The 370 basis point decline in operating margin from 2025Q2 to 2026Q2, despite revenue growth, indicates that the company's high fixed-cost structure is not generating operating leverage at current growth rates. SG&A has remained relatively flat around $1.0B, but the drop in gross profit has disproportionately impacted operating income, which fell from $1.4B to $1.1B. This suggests that management's expense discipline is insufficient to offset contract mix shifts, and investors should watch for any SG&A reduction initiatives.

The near-zero R&D line is atypical for a defense prime, suggesting that the company capitalizes or absorbs development costs within program COGS, which would explain the compressed gross margins. The $1.1B R&D spike in 2024Q4 likely reflects a specific milestone or impairment, but its absence in other quarters makes it difficult to assess ongoing investment intensity. Investors should monitor the FAS/CAS pension adjustment and intangible amortization, which are not visible in this data but could distort cost comparisons.

This trough appears driven by a combination of revenue decline (-6.6% YoY) and a gross margin drop to 16.7%, likely due to adverse contract adjustments or program delays. The subsequent recovery to 10.1% operating margin by 2026Q2 suggests that the company absorbed the shock and is stabilizing, but the path has been uneven. This inflection highlights the vulnerability of Northrop's earnings to program-specific events, and the lasting impact is a more cautious market view on margin predictability.